ALPS Medical Breakthroughs ETF $SBIO Shares Sold by DAVENPORT & Co LLC

DAVENPORT & Co LLC reduced its position in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) by 97.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,100 shares of the company’s stock after selling 474,312 shares during the quarter. DAVENPORT & Co LLC owned about 0.45% of ALPS Medical Breakthroughs ETF worth $569,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fulcrum Equity Management purchased a new stake in ALPS Medical Breakthroughs ETF during the fourth quarter valued at about $384,000. Virtu Financial LLC purchased a new position in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter worth about $650,000. Comerica Bank purchased a new position in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter worth about $27,000. Sterling Investment Advisors Ltd. acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter valued at about $315,000. Finally, Moran Wealth Management LLC lifted its stake in shares of ALPS Medical Breakthroughs ETF by 72.2% in the 3rd quarter. Moran Wealth Management LLC now owns 17,187 shares of the company’s stock valued at $668,000 after purchasing an additional 7,206 shares in the last quarter.

ALPS Medical Breakthroughs ETF Trading Up 8.9%

Shares of NYSEARCA:SBIO opened at $52.34 on Wednesday. The stock has a 50-day simple moving average of $50.85 and a 200-day simple moving average of $47.62. ALPS Medical Breakthroughs ETF has a 1 year low of $22.33 and a 1 year high of $54.79.

ALPS Medical Breakthroughs ETF Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.